Objective: Conflicting data exist regarding the impact of in-utero exposure to maternal combination antiretrovirals. We compared neurodevelopmental outcomes between HIV-exposed-uninfected (HEU) children exposed in utero to three-drug combination antiretroviral therapy (ART) vs. zidovudine (ZDV) monotherapy.
Introduction
Globally, an increasing number of children are exposed in utero to maternal three-drug antiretroviral therapy (ART) [1] . Despite marked reductions in perinatal HIV transmission with maternal ART, important concerns remain regarding the impact of in-utero antiretroviral exposure on child health and neurodevelopment [2] [3] [4] . Exploration of potential effects of in-utero ARTexposure on neurodevelopment in HIV-uninfected children born to HIV-infected mothers [HIV-exposed-uninfected (HEU) children] remains an area of special interest [1] [2] [3] [4] .
The southern African nation of Botswana has the second highest HIV-1 prevalence in the world, with a severe, generalized HIV epidemic affecting 22% of adults aged 15-49 years [5] . HIV infection is predominantly transmitted heterosexually in Botswana, affects all socioeconomic strata, and is not particularly associated with alcohol or substance abuse [6, 7] . Botswana emerged as a regional leader in the provision of mother-to-child HIV transmission (MTCT) prevention services and ART to its citizens [8] . Starting in 2012, the CD4 þ cell count threshold for ART initiation was raised from at least 200 to at least 350 cells/ml, and universal ART in pregnancy regardless of CD4 þ cell count (PMTCT 'Option B') was offered [9] .
The benefits of antiretroviral medicines to prevent MTCT of HIV outweigh their potential for harm [10] . However, data regarding the effects of in-utero antiretroviral exposure on child neurodevelopment have been somewhat conflicting. Prior analyses from populations in developed countries have been fraught with challenges in providing adequate control for potential confounders associated with both maternal HIV infection/antiretroviral use and child neurodevelopment [11] [12] [13] [14] [15] [16] [17] . Limited data capture neurodevelopment in HEU children in resource-limited settings [18] [19] [20] [21] [22] [23] [24] , particularly in Africa, the region most affected by HIV [19] [20] [21] [22] [23] [24] . We sought to compare neurodevelopment in HEU children who were exposed in utero to three-drug ART vs. zidovudine (ZDV) monotherapy, in the context of the generalized HIV epidemic in Botswana. Worse neurodevelopmental outcomes in three-drug ART-exposed children would warrant investigation of safer ART regimens, while similar neurodevelopmental outcomes provide appropriate reassurance regarding the ongoing widespread use of three-drug ART in pregnancy.
Methods

Study design and populations
We conducted a combined analysis of two prospective cohort studies in Botswana (the Tshipidi and Mma Bana studies) in which neurodevelopmental assessments were conducted at 24 months of age among HEU children. In these two studies, children were exposed in utero to ART or to ZDV monotherapy for at least 2 weeks prior to delivery. ART is defined here as receipt of three or more antiretroviral drugs simultaneously.
The Tshipidi study was an observational study, which enrolled consenting HIV-infected women and HIVuninfected women (all Botswana citizens age 18 years or older) during pregnancy or within 1 week of delivery between May 2010 and February 2012 at two sites in Botswana: Gaborone (the capital city) and Mochudi (a nearby village). Only HIV-infected women and their HIV-uninfected children were included in this analysis. Mothers and infants were followed for 24 months postpartum, and received routine clinical care at government facilities (details of study visits/evaluations are below). As Tshipidi was an observational study, maternal antiretroviral regimens were consistent with Botswana government guidelines in use at that time of enrollment [9] . Mothers were promptly evaluated and referred for treatment if they were not already receiving appropriate antiretrovirals at the time of recruitment. Mothers chose feeding methods with counseling per Botswana guidelines [9] . HIV-infected mothers who chose replacement feeding received free formula. HIVexposed children generally received a single dose of nevirapine and 1 month of ZDV. At study entry, maternal demographic, socioeconomic, and health predictors were collected, including maternal CD4 þ cell count and HIV-1 RNA. Infant evaluations included HIV-1 DNA PCR at birth, 1, 6, 12 months and HIV-1 ELISA at 18 months postpartum. At each interval (and at 24 months), infant height, weight, head circumference, clinical history, medication history, feeding history, and physical examination were documented.
The Mma Bana study was a randomized MTCT prevention trial, which enrolled pregnant HIV-infected women between July 2006 and May 2008 in four sites in Botswana (the same two as the Tshipidi study and the village of Molepolole as well as the town of Lobatse). The Mma Bana trial design and primary results have been previously published [25] . As part of the current study we added neurodevelopmental testing of children at 24 months of age to the Mma Bana trial cohort (thus only a subset of Mma Bana participants had the opportunity to take part in this substudy of neurodevelopment). In Mma Bana, HIV-infected mothers with CD4 þ cell counts of 200 cells/ml or more were randomized to receive either Trizivir [abacavir/ZDV/ lamivudine -'triplenucleoside reverse-transcriptase inhibitor (NRTI) group'] or Kaletra/Combivir (lopinavir-ritonavir/ ZDV/lamivudine -'protease-inhibitor (PI) group'], taken during pregnancy through 6 months postpartum or more (during the period of breastfeeding). Women with baseline CD4 þ cell count less than 200 cells/ml received nevirapine, ZDV, and lamivudine antepartum and indefinitely postpartum (the 'observational group') [25] . Mma Bana participants were counseled to exclusively breastfeed and to wean at 6 months. Infants received a single dose of nevirapine and 1 month of ZDV. Very similar baseline factors and follow-up evaluations were conducted in the Mma Bana study as within Tshipidi, following a similar visit schedule.
HIV tests and CD4
þ cell counts were performed at the approved Botswana Harvard HIV Reference Laboratory in Gaborone. For the Mma Bana and Tshipidi studies, maternal HIV infection was confirmed during the identified pregnancy or within 7 days of delivery [26] . [27] . The neurodevelopmental assessments were translated into Setswana and back translated. All instruments were reviewed by local personnel, and modifications or adaptations were made as needed. All tests were then piloted. The Bayley-III required further modifications and was re-piloted. Trained study personnel, research nurses, administered the Bayley-III, the DMC and all study questionnaires. All study questionnaires were completed by direct interview. The Social-Emotional and Adaptive Behavior sections of the Bayley-III were not administered, as they were not culturally appropriate; these were replaced with parent report measures of typical behaviors of the child in the home setting, including the Development Milestones Checklist (DMC), which was developed and normed in Kenya [25] [26] [27] [28] . Data were entered into standardized case report forms at the study sites. An invalid score was assigned to children who were unable to complete neurodevelopmental testing or whose physical or behavioral problems were suggestive of potential clinical impairment. Invalid scores were noted by clinical assessors and confirmed by the lead neuropsychologist (B.K.). Assessor performance was monitored periodically through video and/or direct observation by study coordinators and lead neuropsychologist (B.K.). Reliability was checked by observation of testing tapes and monitoring by the study coordinator.
Statistical analyses
The primary comparison of interest in this analysis was between neurodevelopmental outcomes in HEU children exposed in utero either to ART (from either study) or ZDV (from the Tshipidi study only), to determine potential risk of either antiretroviral exposure.
The primary outcomes of interest were the 24-month Bayley-III subscale raw scores (Cognitive, Gross Motor, Fine Motor, Expressive Language, and Receptive Language) and the DMC subscale scores (Loco-motor, Fine motor, Language, and Personal-Social). Unadjusted and adjusted linear regression models compared differences in HEU child mean neurodevelopment exposed to ARTor ZDV. Cohen's d standardized effect sizes for mean differences were reported [29] . Only valid assessments were included in primary analyses. Infants with an invalid score for a specific neurodevelopmental domain were excluded from analyses for that outcome, but included in any analyses of outcomes for which they had valid scores. Demographic and maternal health characteristics were summarized and compared according to cohort (Mma Bana and Tshipidi) and antiretroviral exposure, using means and standard deviations, or medians for nonnormally distributed characteristics, and t tests or ANOVA tests for categorical measures.
We assessed differences in baseline characteristics between those who did and did not complete a neurodevelopment assessment. We also compared baseline characteristics for those with invalid or low scores (1 SD below the domainspecific mean) vs. higher valid scores. Univariate and multivariate logistic regression models were used to assess predictors of a composite adverse outcome (either a low score or an invalid score).
Potential confounders were identified using a priori knowledge of predictors of poor neurodevelopmental outcomes from other studies. Directed acyclic graphs were used to delineate assumptions regarding the causal pathway of interest. Potential confounders included maternal health-related factors (such as antenatal HIV-1 RNA, maternal CD4 þ cell counts, and maternal age), socioeconomic factors (including education, income, toilet facilities, and availability of electricity and water in the household), and the year of neurodevelopmental testing. Further measures within the Tshipidi cohort included food security, type of cooking method employed within the household, and maternal depression, alcohol, and substance use. All characteristics with unadjusted P < 0.20 for association with a specific neurodevelopmental domain score were initially included in adjusted models. Covariates with P > 0.20 in multivariate models were subsequently excluded.
Around 12% of eligible study participants had missing results for one or more Bayley-III domains (Supplemental Table 2 , http://links.lww.com/QAD/B240), with less than 0.5% having invalid test results. Restricting our analysis to individuals with complete test results could introduce bias if exposure to ART were associated with completing the Bayley-III and neurodevelopment differed between those who completed the assessment and those who did not. To adjust for this potential selection bias, we computed inverse probability of censoring weights. Each child who completed the domain of interest received a weight inversely proportional to the estimated probability of not being censored (i.e., completing the Bayley-III). Weights were computed using logistic regression models including ART exposure and other baseline covariates. The weights were stabilized and used in sensitivity analyses evaluating ART exposure and Bayley-III domain scores, adjusted for the same covariates.
Low birth-weight (<2500 g) and preterm birth (<37 weeks of gestation) were considered to be potential mediators, as they have been identified in prior literature to be on the causal pathway between antiretroviral exposure and neurodevelopment [30, 31] . Primary models excluded these factors, but in sensitivity analyses, models were further adjusted for these birth characteristics to evaluate the impact on findings.
Nearly all children in Mma Bana were both ART-exposed and breastfed, whereas nearly all children in Tshipidi were formula-fed. Therefore, the reference group for the primary comparison of interest was predominantly formula-fed (i.e., the reference group being formed by the ZDV-exposed children enrolled in Tshipidi). Decisions regarding feeding were generally made prior to exposure (in accordance with study recruitment of breastfeeding mothers within Mma Bana [26] or national policy recommendations regarding formula feeding during Tshipidi [9] ). To address the potential effect of feeding strategy, we restricted a subanalysis to only formula-fed children within Tshipidi. This approach also accounted for differences in conditions under which the two studies were conducted. Finally, the Tshipidi-only analysis also offered opportunity to control for a wider array of potential confounders (such as maternal depression and food insecurity) for which data were collected in only this study.
Results
Enrollment and neurodevelopmental testing completeness Among the 910 live-born children enrolled in Tshipidi, 453 were HEU. Of these, 412 children were alive and attended visits at 24 months, of which 313 completed at least one valid Bayley-III test and the parents of 357 completed the DMC (Fig. 1) . Among 709 live-born infants enrolled in the two randomized arms and observational cohort of the Mma Bana study, 219 completed at least one valid Bayley-III domain and 252 had a completed DMC at 2 years. The majority of Mma Bana participants were not approached for testing, as they had already exceeded the age for neurodevelopmental evaluation by the time this substudy was initiated. Additionally, limitations on study staff time at the onset of the neurodevelopmental assessments meant that many eligible children were not tested (n ¼ 334, Supplemental (Fig. 1 ).
Maternal and infant clinical and sociodemographic characteristics of these 598 HEU participants are summarized in Table 1 [32] [33] [34] [35] . According to ART exposure status and study cohort. The majority (65%) of HEU children were ART-exposed, with 68% of the ART-exposed children enrolled in Mma Bana and 32% in Tshipidi. All ZDV-exposed HEU children were in the Tshipidi study. Almost all of children in Mma Bana were both breastfed and ART-exposed, whereas most (90%) Tshipidi infants were formula-fed. Entry median viral load was higher among mothers in Mma Bana than in Tshipidi (likely because many women enrolling in Tshipidi were taking antiretrovirals at enrollment, while Mma Bana participants were not). Entry median maternal CD4 þ cell count was lower among Mma Bana mothers than in Tshipidi. Mothers were similar with regards to age, education, and income across the cohorts and according to ART exposure.
Neurodevelopmental outcomes among HIV-exposed-uninfected children participating in both the Mma Bana and Tshipidi cohorts (by antiretroviral-exposure group, three-drug antiretroviral therapy vs. zidovudine only) Figure 2a and b shows crude unadjusted mean Bayley-III and DMC scores by antiretroviral exposure and feeding groups. Each neurodevelopment domain was significantly associated with at least one previously described clinical, socioeconomic or environmental predictor (Supplemental Tables 3-6, http://links.lww.com/QAD/B240). Crude unadjusted Bayley-III means scores were highest for all domains in the ART-exposed breastfed infants (Fig. 2a) . This finding was not, however, seen with the DMC crude mean scores (Fig. 2b) . Mean differences in Bayley-III and DMC outcomes between ART-exposed and ZDV-exposed children are summarized in Table 2 , both with and without adjustment for calendar year and other confounders. ART-exposed children had similar adjusted neurodevelopment scores across all domains of the Bayley-III and DMC scale. When accounting for missing assessments using IP weighted regression, results were similar to those shown in Table 2 (data not shown).
Neurodevelopmental outcomes among formula-fed HIV-exposed-uninfected children who participated in the Tshipidi cohort by antiretroviral exposure group (three-drug antiretroviral therapy vs. zidovudine only) This secondary analysis was performed to evaluate the potential effect of three-drug ART vs. ZDV on neurodevelopment, independent of feeding-method or study cohort. In addition, more extensive baseline characteristics were collected within Tshipidi than was possible for Mma Bana (Supplemental Tables 3-6 , http:// links.lww.com/QAD/B240). Similar to our main analysis, no significant differences were observed among those exposed to ART when compared to ZDV monotherapy across all domains of the Bayley-III and DMC scale (Table 3) . Sensitivity analyses additionally adjusting for birth-weight and preterm birth produced similar findings to the above results (Supplemental Tables 7-8 , http://links.lww.com/QAD/B240). Similar results were observed when applying IP weighted regression to account for eligible participants without assessments (data not shown).
In-utero ART and neurodevelopment Chaudhury et al. 1177 Tables 10-11 , http://links.lww.com/QAD/B240).
In-utero ART and neurodevelopment Chaudhury et al. 1179 Median (IQR) gestational age in weeks at ARV start (among those women commencing ARV during current pregnancy). Food insecurity as measured by an adapted Household Food Insecurity Access Scale [32] . Means reported reflect highest value during study follow-up prior to neurodevelopmental testing for each mother, for example, mean score using highest score on the 2 Beck Depression Scale [33] (i.e. worse depression). Mean score using highest score for a given mother's assessment of her 3 social support [34] (i.e., worse support) 3 Mean score using the highest score for a given mother's assessment of her perceived experience of 4 stigma [35] (i.e., worse stigma). e Any alcohol use or tobacco use during current pregnancy.
Discussion
Neurodevelopmental outcomes among 24-month-old HEU children who were exposed in utero to three-drug ART vs. ZDV monotherapy were similar across all domains/subscales tested, including after controlling for potential confounders such as maternal viral load, CD4 þ cell count and age, education, and income. Findings provide reassurance that HEU child neurodevelopment, at two years of age, is not adversely affected by in-utero combination ART exposure [13, 15] . Furthermore, maternal ART during pregnancy while breastfeeding is likely to lead to 24-month neurodevelopmental outcomes comparable to those of formula-fed children whose mothers took ZDV monotherapy. The subanalysis within the Tshipidi cohort within formula-fed children only, further affirmed that ART-exposure in utero was not associated with any neurodevelopmental deficit.
The strengths of our study include the relatively high participation rate among eligible cohort members, large sample size, collection of data on a broad range of potential confounders relevant to sub-Saharan Africa, and context of a generalized epidemic where HIV-infected mothers were more representative of the general population, when compared with Western epidemics. The study had 80% power to detect a difference of 0.27-0.38 standard deviations between mean scores of children exposed in utero to ART vs. ZDV, with sufficient power to detect a range of neurodevelopmental differences.
Our study also has several limitations. Children not tested differed from those who were tested (Supplemental Table  9 , http://links.lww.com/QAD/B240), according to prematurity and birth-weight. Sensitivity analyses incorporating prematurity and birth-weight did not alter adjusted estimates. Our secondary analysis restricted to formula-fed children in Tshipidi only, yielded very similar results. Approximately 85% of the ART-exposed children's mothers were ART-naive at baseline. Given the small proportion (around 15%) of prevalent users we did not expect prevalent user bias to significantly affect our results. The majority of women commenced ART during pregnancy, between 18 and 34 weeks' gestation and had a similar duration of use to the comparison group (median 12.3 weeks of ARTor 11 weeks of ZDV). Little is known regarding the exact timing and duration of the critical window of exposure; however, outstanding concerns of potential toxicity, following any in-utero exposure to antiretroviral medicines remain. This study was underpowered to further discern differences between trimester of exposure and outcomes.
Our study tested children at 2 years of age and found no differences according to antiretroviral exposure; however, findings cannot be generalized to older children. A small number of studies have followed children into later ages to negate negative neurodevelopmental outcomes [12, 36] .
In-utero ART and neurodevelopment Chaudhury et al. 1181 Table 2 . Crude means, unadjusted and adjusted mean differences, and effect sizes in Bayley-III and DMC neurodevelopment domain scores at age 24 months for. ART-exposed children in our study were exposed to abacavir/ZDV/lamivudine or lopinavir/ritonavir/ZDV/ lamivudine within Mma Bana, and a range of ART regimens within Tshipidi (ZDV/lamivudine or tenofovir disoproxil/emtricitabine, in combination with nevirapine, or lopinavir/ritonavir, or atazanavir/ritonavir). Sirois et al. [11] reported on the neurodevelopment of 374 infants with Bayley-III evaluations in the Pediatric HIV/AIDS Cohort Study Surveillance Monitoring for Antiretroviral Therapy Toxicities (SMARTT), a US based multisite cohort study, at a median age of 12.7 months, and found no association with overall ART, specific antiretroviral regimen, or antiretroviral prophylaxis exposure in utero. In this study, the adjusted mean score for language was within age-expected ranges but significantly lower for infants exposed to atazanavir in utero, confirmed in a follow-up analysis within SMARTT by Caniglia et al. [37] .
Neurodevelopment
Studies within resource-limited settings have not examined the potential effects of in-utero exposure to maternal antiretroviral use on neurodevelopment among HEU children [18] [19] [20] [21] [22] [23] [24] , particularly within Africa. Given the large number of antiretroviral-exposed HEU infants that continue to be born globally, and the evolving treatment and landscape, surveillance of potential effects through standardized approaches, will be of continued importance, to examine differing antiretroviral exposures, across a range of ages and neurophysiological functions [38] .
Conclusion
HEU child neurodevelopment at 24 months of age does not differ according to exposure in utero to three-drug ART vs. ZDV alone. Our data provide additional support that benefits of three-drug ART use during pregnancy, particularly when combined with breastfeeding, outweigh potential risks for HEU children.
